Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

JNJ 105.55 -1.26 (-1.18%)
price chart
J&J's Global Creative Review Nears Finish
Johnson & Johnson is close to concluding its global review of creative responsibilities for its over-the-counter brands and sources expect the bulk of the business to be consolidated at three roster shops: DDB, BBDO and JWT.
Related articles »  
Johnson & Johnson Agrees to Settle Five Rispersal Suits
Johnson & Johnson (JNJ) agreed to settle five lawsuits over claims that its antipsychotic drug Risperdal caused increased breast-tissue growth in boys.
J&J aims to block ex-FDA chief's testimony in Risperdal case  FiercePharma
Related articles »  
Johnson & Johnson's Q3 Earnings: What We Are Watching
Johnson & Johnson is set to announce its Q3 earnings for 2012 on Tuesday, October 16. We expect the earnings to get a boost mainly on continued strong performance by the pharmaceutical franchise and the company's acquisition of Swiss medical device ...
Johnson & Johnson third-quarter profit hit by charges, currency fluctuations  The Star-Ledger -
Johnson & Johnson Tops Street in 3Q, Lifts Outlook  Fox Business
Related articles »  
Tylenol and the Legacy of J&J's James Burke
This post is in partnership with Knowledge@Wharton, the online research and business analysis journal of the Wharton School of the University of Pennsylvania.
Johnson & Johnson, Mayor Booker Partner for Better Health
When I say the words Johnson & Johnson, you can probably smell the baby shampoo we all used as children and which you may still use with your own children.
Johnson & Johnson facing massive class action
Medical giant Johnson & Johnson is facing its third class action in Australia in as many years, with a case filed in the Federal Court yesterday which relates to a product called transvaginal mesh.
Related articles »  
The Good, The Bad And The Ugly: Johnson & Johnson
They have all been recalled by Johnson & Johnson (NYSE:JNJ) between 2009 and 2012 for everything from the relatively inconsequential (Motrin caplets dissolving too slowly) to the very serious (bacterial contamination in Infant's and Children's Tylenol).
Uncertainty At Johnson & Johnson Creates Risk
At minimum, current shareholders should hold Johnson & Johnson (NYSE:JNJ) until the next earnings release; interested investors should initiate a position this month.
Johnson & Johnson: Buying This Cash Cow With 4.8% Discount Through Options
Johnson & Johnson (NYSE:JNJ) is the world's largest and most diverse health-care company, which comprises three divisions: pharmaceutical, medical devices and diagnostics, and consumer.
Related articles »  
Gores Group to Buy Johnson & Johnson Unit
The Gores Group on Monday said that it has agreed to acquire the maker of a medical device that's used to treat blood cancer from a unit of New Jersey health care conglomerate Johnson & Johnson. Therakos is a 25-year-old company based in Raritan, N.J ...
Gores Group to buy Therakos from Ortho-Clinical Diagnostics
Related articles »